For the quarter ended June 30 2023, ASCENDIS PHARMA A/S ($NASDAQ:ASND) reported total revenue of EUR 47.4 million, a 6.2 million increase from the same quarter the prior year. Net income was reported at EUR -121.4 million, a decrease of -81.3 million from the same quarter in the prior year.
Ascendis Pharma A/S reported their second quarter earnings results for the fiscal year 2023 on Tuesday. The company’s stock opened at $97.4 and closed at $99.7, representing a 1.5% increase from the previous closing price of $98.3. The company’s strong performance in the quarter can be attributed to their extensive product portfolio, which includes several innovative drugs and treatments across a variety of therapeutic areas.
In addition, the company has been able to maintain a positive net income margin and return on equity despite the challenging market conditions. This has allowed them to continue to invest in research and development activities, allowing them to stay ahead of their competitors. Overall, the stock experienced a good run in the second quarter of FY2023, with the share price increasing by more than 1.5%. This is a positive sign for shareholders who have been patiently waiting for the stock to reach its full potential. As the company continues to launch new products and strengthen its core operations, it is expected that the stock will experience further growth in the coming months. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for ASND. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for ASND. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for ASND. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for ASND are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – ASND Stock Fair Value Calculator
We recently conducted an analysis of ASCENDIS PHARMA A/S’s fundamentals and have concluded that the intrinsic value of the company’s share is around $1470.8. This value was calculated using our proprietary Valuation Line. Currently, ASCENDIS PHARMA A/S stock is trading at $99.7, which indicates that its shares are undervalued by 93.2%. More…
Risk Rating Analysis
Star Chart Analysis
Ascendis Pharma A/S, Hard to Treat Diseases Inc, Shanghai Bio-heart Biological Technology Co Ltd, and China Regenerative Medicine International Ltd are all companies that focus on developing treatments for hard-to-treat diseases. While each company has its own unique approach, they all share the common goal of helping patients with difficult-to-treat conditions.
– Hard to Treat Diseases Inc ($OTCPK:HTDS)
Shanghai Bio-heart Biological Technology Co Ltd is a Chinese company that focuses on the research and development of cardiovascular therapeutics. The company’s market cap as of 2022 is 11.97 billion, and its ROE is -18.92%. Shanghai Bio-heart Biological Technology Co Ltd’s products include treatments for heart failure, myocardial infarction, and arrhythmia.
– Shanghai Bio-heart Biological Technology Co Ltd ($SEHK:02185)
China Regenerative Medicine International Ltd. is a Hong Kong-based investment holding company principally engaged in the provision of medical services. The Company operates its business through three segments. The In-patient Services segment is engaged in the provision of medical services to in-patients. The Out-patient Services segment is engaged in the provision of medical services to out-patients. The Others segment is engaged in the provision of other services. The Company operates a hospital, which is located in Shenzhen, the People’s Republic of China (PRC).
Investors should take note of the results from ASCENDIS PHARMA A/S’ second quarter of FY2023 as total revenue increased by 6.2 million from the same quarter last year, although net income decreased by -81.3 million. This suggests that while revenue is increasing in this sector, profit margins are shrinking which could be a cause for concern. Investors should carefully examine the company’s balance sheet and financials to determine if investing in this stock is right for them. Additionally, monitoring of industry trends and competitor performance should be considered when evaluating the potential for a long-term investment in ASCENDIS PHARMA A/S.